Ftse Mib
34.632,47
0,65%
DAX
19.440,34
1,15%
S&P 500
5.751,06
0,10%
NASDAQ
18.215,44
0,14%
Bitcoin
65.488,42
0,47%
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Ionis Pharmaceuticals Inc (IONS) Ionis Pharmaceuticals Inc (IONS) Notizie

IONS

Ionis Pharmaceuticals (IONS)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:IONS
DataOraFonteTitoloSimboloCompagnia
10/09/202423:19Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IONSIonis Pharmaceuticals Inc
10/09/202403:10PR Newswire (US)Ionis announces pricing of $500.3 million public offeringNASDAQ:IONSIonis Pharmaceuticals Inc
09/09/202422:33Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IONSIonis Pharmaceuticals Inc
09/09/202422:20PR Newswire (US)Ionis announces proposed public offering of common stockNASDAQ:IONSIonis Pharmaceuticals Inc
05/09/202403:51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
05/09/202403:33Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:IONSIonis Pharmaceuticals Inc
05/09/202403:33Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:IONSIonis Pharmaceuticals Inc
04/09/202413:30GlobeNewswire Inc.Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMANASDAQ:IONSIonis Pharmaceuticals Inc
28/08/202413:05PR Newswire (US)Ionis to present at upcoming investor conferencesNASDAQ:IONSIonis Pharmaceuticals Inc
05/08/202422:11Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
05/08/202421:35Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:IONSIonis Pharmaceuticals Inc
01/08/202422:57Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IONSIonis Pharmaceuticals Inc
01/08/202413:00PR Newswire (US)Ionis reports second quarter 2024 financial resultsNASDAQ:IONSIonis Pharmaceuticals Inc
31/07/202415:00PR Newswire (US)Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for Administration of nusinersenNASDAQ:IONSIonis Pharmaceuticals Inc
22/07/202413:00PR Newswire (US)Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndromeNASDAQ:IONSIonis Pharmaceuticals Inc
19/07/202414:24PR Newswire (US)Ionis to hold second quarter 2024 financial results webcastNASDAQ:IONSIonis Pharmaceuticals Inc
18/07/202413:00PR Newswire (US)Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander diseaseNASDAQ:IONSIonis Pharmaceuticals Inc
08/07/202413:05PR Newswire (US)Ionis announces webcast to report HALOS study results for ION582 in Angelman syndromeNASDAQ:IONSIonis Pharmaceuticals Inc
25/06/202412:55PR Newswire (US)Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completedNASDAQ:IONSIonis Pharmaceuticals Inc
18/06/202413:00PR Newswire (US)Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedemaNASDAQ:IONSIonis Pharmaceuticals Inc
17/06/202422:09PR Newswire (US)Ionis to present at TD Cowen Genetic Medicines & RNA SummitNASDAQ:IONSIonis Pharmaceuticals Inc
31/05/202413:00PR Newswire (US)Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedemaNASDAQ:IONSIonis Pharmaceuticals Inc
28/05/202413:00PR Newswire (US)Ionis to hold donidalorsen Phase 3 data webcastNASDAQ:IONSIonis Pharmaceuticals Inc
23/05/202413:00PR Newswire (US)New data from the Phase 3 NEURO-TTRansform study evaluating WAINUA™ (eplontersen) to be presented at the 2024 International Symposium on Amyloidosis (ISA)NASDAQ:IONSIonis Pharmaceuticals Inc
16/05/202413:30GlobeNewswire Inc.Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral SclerosisNASDAQ:IONSIonis Pharmaceuticals Inc
16/05/202413:30PR Newswire (US)Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral SclerosisNASDAQ:IONSIonis Pharmaceuticals Inc
16/05/202413:00PR Newswire (US)Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndromeNASDAQ:IONSIonis Pharmaceuticals Inc
15/05/202413:05PR Newswire (US)Ionis to host 2024 virtual Annual Meeting of StockholdersNASDAQ:IONSIonis Pharmaceuticals Inc
07/05/202413:00PR Newswire (US)Ionis reports first quarter 2024 financial resultsNASDAQ:IONSIonis Pharmaceuticals Inc
25/04/202413:00PR Newswire (US)Ionis Publishes 2023 Corporate Responsibility ReportNASDAQ:IONSIonis Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:IONS

La tua Cronologia

BIT
MONC
Moncler
BIT
STLAM
Stellantis NV
BIT
UCG
Unicredit
BIT
ENI
Eni
BIT
ISP
Intesa Sanpaolo
BIT
STMMI
ST Microelectronics
BIT
RACE
Ferrari NV
BIT
ENEL
Enel
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
BPE
Bper Banca
BIT
PRY
Prysmian
BIT
SPM
Saipem
BIT
BC
Brunello Cucinelli
BIT
CPR
Davide Campari
BIT
BAMI
Banco BPM
BIT
IVG
Iveco Group NV
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network